secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001193125-26-059716
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Artiva Biotherapeutics appoints former AbbVie SVP Elaine Sorg as Class I director
--------------------------------------------------------------------------------

- Elaine Sorg appointed as Class I director on Feb 18, 2026, term expiring at 2028 annual meeting.
- No arrangements or transactions requiring disclosure under Item 404(a) were identified.
- Compensation includes $40k annual cash retainer and initial option for 27,500 shares; one-third vests immediately, remainder monthly over two years.
- Automatic annual option grants of 13,750 shares on each annual meeting date vest on one-year anniversary or next annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526059716/0001193125-26-059716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526059716/artv-20250128.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-059716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer